Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs
Clinical trial NCT06475443 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06475443
- Sponsor
- Henan Cancer Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-15
- Primary completion
- 2026-06-30
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.